Results 21 to 30 of about 2,052,688 (283)
Tumor Biology, 2017 Chimeric antigen receptor modified T cell–based immunotherapy is revolutionizing the field of cancer treatment. However, its potential in treating bile duct carcinoma has not been fully explored.
Jie-Ying Xu +9 more
doaj +1 more source
Journal of Medical Case Reports, 2022 Background Multiple myeloma remains incurable despite treatment advancements over the last 20 years. LCAR-B38M Cells in Treating Relapsed/Refractory Multiple Myeloma was a phase 1, first-in-human, investigator-initiated study in relapsed/refractory ...
Bai-Yan Wang +20 more
doaj +1 more source
Combinatorial functions of two chimeric antibodies directed to human CD4 and one directed to the a-chain of the human interleukin-2 receptor [PDF]
, 1992 The general feasibility of chimerization of monoclonal antibodies (mAbs) has already been shown for a large number of them. In order to evaluate in vitro parameters relevant to immunosuppressive therapy, we have chimerized and synthesized two anti-CD4 ...
Schwirzke, Marina +10 more
core +1 more source
Haematologica, 2016 Adoptive transfer of chimeric antigen receptor-transduced T cells is a promising strategy for cancer immunotherapy. The CD38 molecule, with its high expression on multiple myeloma cells, appears a suitable target for antibody therapy.
Esther Drent +13 more
doaj +1 more source
Chimeric antigen receptor T cell therapies for thoracic cancers-challenges and opportunities
, 2020 Chimeric antigen receptor T cell therapies for thoracic cancers— challenges and ...
Slaney, CY +4 more
core +1 more source
Ligand-based CAR-T cell: Different strategies to drive T cells in future new treatments
Frontiers in Immunology, 2022 Chimeric antigen receptor (CAR)-based therapies are presented as innovative treatments for multiple malignancies. Despite their clinical success, there is scientific evidence of the limitations of these therapies mainly due to immunogenicity issues ...
Alejandro Ramírez-Chacón +13 more
doaj +1 more source
The Chimeric Antigen Receptor Detection Toolkit
Frontiers in Immunology, 2020 Chimeric antigen receptor-T (CAR-T) cell therapy is a promising frontier of immunoengineering and cancer immunotherapy. Methods that detect, quantify, track, and visualize the CAR, have catalyzed the rapid advancement of CAR-T cell therapy from ...
Yifei Hu, Yifei Hu, Jun Huang
doaj +1 more source
Unlocking the potential of Tregs: innovations in CAR technology
Frontiers in Molecular Biosciences, 2023 Regulatory T cells (Tregs) adoptive immunotherapy is emerging as a viable treatment option for both autoimmune and alloimmune diseases. However, numerous challenges remain, including limitations related to cell number, availability of target-specific ...
Christopher J. Requejo Cier +2 more
doaj +1 more source
Drug functional remapping: a new promise for tumor immunotherapy
Frontiers in OncologyThe research and development of new anti-cancer drugs face challenges such as high costs, lengthy development cycles, and limited data on side effects.
Jiayi Dong +27 more
doaj +1 more source
Chimeric antigen receptor T-cells in multiple myeloma: Present and future [PDF]
This is a brief summary of various general contemporary topics regarding chimeric antigen receptor (CAR) T-cells in multiple myeloma (MM)
Plata, Carlos
core +4 more sources